Rare Events, Rare Disease: “Theoretical” Issues Central To FDA Soliris Review
Executive Summary
The effect of Alexion's paroxysmal nocturnal hemoglobinuria therapy Soliris (eculizumab) on thrombosis, a major clinical problem associated with the rare blood disorder, was one of the most contested issues in the review of the Soliris BLA, FDA review documents suggest
You may also be interested in...
Alexion’s Soliris Blood Treatment Will Cost Almost $400,000 Per Year
Alexion Pharmaceuticals is launching its paroxysmal nocturnal hemoglubinuria Soliris (eculizumab) with a treatment support service with case managers to help facilitate reimbursement
PTC’s Upstaza Takes Gene Therapy Straight To Brain (And US FDA); Translarna To Return Mid-Year
In a year full of regulatory milestones for the firm, PTC Therapeutics hopes to set some approval precedents – and basically hopes its candidates have an easier time of it than they have had before.
BeiGene’s Tevimbra And The End Of The COVID Inspection Era
US FDA approves the PD-1 inhibitor 20 months after user fee goal, resolving one of the last applications delayed by China’s extended pandemic travel restrictions.